探索基于语音的自动认知标记的神经相关性,通过静止状态的功能连接在衰老和阿尔茨海默病风险中
Qingyue Li1, Zampeta-Sofia Alexopoulou2, Martin Dyrba3
1Department of Psychosomatic Medicine, Rostock University Medical Center, Gehlsheimer Str. 20, Rostock, 18147, Germany. Qingyue.Li@med.uni-rostock.de.
Alzheimer's research & therapy
|February 24, 2026
概括
数字语音分析显示,在患阿尔茨海默病风险较高的人群中,检测大脑连接变化的能力有限. 需要进一步的研究来验证这些基于语音的认知评估,以监测大脑网络的改变.
科学领域:
- 神经科学是一个神经科学.
- 认知科学 认知科学
- 计算语言学 计算语言学
背景情况:
- 数字语音评估为检测认知衰退提供了可扩展的方法.
- 阿尔茨海默病的谱系与大脑网络中的功能连接 (FC) 发生变化有关.
- 研究数字语音特征与大脑网络改变之间的联系至关重要.
研究的目的:
- 确定基于数字语音的认知分数和个体语音特征是否与阿尔茨海默氏病谱中的功能连接 (FC) 变化相关.
- 探索与任务相关的大脑网络中的关联.
主要方法:
- 在德国PROSPECT-AD研究中分析了129名参与者 (健康到轻度认知障碍) 的数据.
- 语音特征来自于自动电话管理的语义语言流 (SVF) 和口头学习任务 (VLT).
- 静态fMRI用于评估FC,通过ICA和双回归确定内在连接网络;用于分析的基于 permutation 的回归.
主要成果:
- 左中旋中增加的语言网络连接与SVF时集群切换相关.
- 总体认知复合分数和FC之间没有发现显著的关联.
- 个别的SVF和VLT语音功能显示了执行,语言和默认模式网络之间的网络特定关联.
结论:
- 目前,数字语音评估对于检测风险人群中FC变化的效用有限.
- 进一步验证是必不可少的,需要补充方法,更短的评估间隔和独立的队列.
- 确定监测大脑网络变化的可靠性和临床相关性需要进一步的研究.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.8K
09:01A Method for Investigating Age-related Differences in the Functional Connectivity of Cognitive Control Networks Associated with Dimensional Change Card Sort Performance
Published on: May 7, 2014
10.6K
相关概念视频
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
